Phio Pharmaceuticals Corp. will participate in the Sidoti Micro-Cap Virtual Investor Conference on January 21-22, 2026. CEO and Chairman Robert Bitterman is scheduled to present an update on the company's proprietary INTASYL siRNA technology and ongoing clinical trial with lead compound PH-762 for the treatment of skin cancers. The presentation will take place on January 22, 2026, at 1:45 PM ET, and the event will also offer one-on-one meetings with investors throughout both days. Registration is free and open to all interested parties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 280343) on January 15, 2026, and is solely responsible for the information contained therein.